Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
44%
Ph phase_3
1
11%
Ph phase_4
1
11%
Ph not_applicable
2
22%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(1)
Other(5)

Detailed Status

unknown5
Active, not recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (50.0%)
Phase 31 (12.5%)
Phase 41 (12.5%)
N/A2 (25.0%)

Trials by Status

unknown556%
completed111%
active_not_recruiting333%

Recent Activity

3 active trials
Showing 5 of 9
active_not_recruiting

Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence

NCT03283540
active_not_recruitingphase_2

Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29

NCT05253846
active_not_recruitingphase_2

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

NCT04543695
unknownphase_2

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

NCT05763927
unknownphase_2

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

NCT04664504
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03283540

Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence

Active Not Recruiting
NCT05253846Phase 2

Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29

Active Not Recruiting
NCT04543695Phase 2

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Active Not Recruiting
NCT05763927Phase 2

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Unknown
NCT04664504Phase 2

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Unknown
NCT04747951Phase 4

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Unknown
NCT01585727Not Applicable

Intraoperative Monitoring of the Pelvic Autonomic Nerves

Completed
NCT03177382Phase 3

Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors

Unknown
NCT03071198Not Applicable

Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy

Unknown

All 9 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
9